BIOAFFINITY TECHNOLOGIES, INC. – CURRENT REPORT ON FORM 8-K

BioAffinity Technologies, Inc. (the “Company”) announced the consummation of a best efforts public offering on June 16, 2026. The offering raised approximately $3.2 million in aggregate gross proceeds before deducting fees and expenses. The proceeds are intended for working capital and general corporate purposes. The offering included 1,040,000 shares of common stock at $0.80 per share and pre-funded warrants to purchase up to 2,960,000 shares of common stock at $0.793 per pre-funded warrant. The Company entered into a securities purchase agreement with investors, which includes restrictions on issuing additional stock or engaging in variable rate transactions for specified periods post-offering. A placement agency agreement was also executed with WallachBeth Capital LLC, who acted as the placement agent for a fee of 7.5% of gross proceeds, plus $120,000 in expenses. The Company has approximately 6,283,061 shares of common stock outstanding as of the report date. The filing also details the terms of the pre-funded warrants, their exercise, and registration under the Securities Act of 1933.